An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. by Lopes, Renato D et al.
American Heart Journal 200 (2018) 17–23
Contents lists available at ScienceDirect
American Heart JournalTrial DesignAn open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the
safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in
patients with atrial ﬁbrillation and acute coronary syndrome and/or
percutaneous coronary intervention: Rationale and design of the
AUGUSTUS trialRenato D. Lopes, MD, MHS, PhD a,⁎, Amit N. Vora, MD, MPHa, Danny Liaw, MDb, Christopher B. Granger, MDa,
Harald Darius, MDc, Shaun G. Goodman, MD, MSc d, Roxana Mehran, MDe,
Stephan Windecker, MD f, John H. Alexander, MD, MHS a
a Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
b Bristol-Myers Squibb, Princeton, NJ
c Vivantes Neukoelln Medical Center, Berlin, Germany
d Terrence Donnelly Heart Center, St Michael's Hospital, University of Toronto, Ontario, and Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada
e Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and Cardiovascular Research Foundation, New York, NY
f Swiss Cardiovascular Center, Bern, SwitzerlandClinicalTrials.gov: NCT02415400.
Stuart J. Connolly, MD, served as guest editor for this
⁎ Reprint requests: Renato D. Lopes, MD, MHS, PhD, D
Duke University School of Medicine, Durham, NC 27705.
E-mail address: renato.lopes@dm.duke.edu (R.D. Lope
https://doi.org/10.1016/j.ahj.2018.03.001
0002-8703/© 2018 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 14 December 2017
Accepted 3 March 2018Background: The optimal antithrombotic strategy for patients with atrial ﬁbrillation (AF) who develop acute cor-
onary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of
bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy
with antiplatelet agents is required to minimize recurrent ischemic events.
Design: AUGUSTUS is an international, multicenter randomized trial with a 2 × 2 factorial design to compare
apixaban with vitamin K antagonists and aspirin with placebo in patients with AF who develop ACS and/or un-
dergo PCI and are receiving a P2Y12 inhibitor. Patients will be evaluated for eligibility during their ACS and/or
PCI hospitalization. The primary outcome is the composite ofmajor and clinically relevant nonmajor bleeding de-
ﬁned by the International Society on Thrombosis and Haemostasis. A key secondary outcome is the composite of
all-cause death and all-cause hospitalization. Other secondary objectives are to evaluate ischemic outcomes in-
cluding the composite of death, myocardial infarction, stroke, stent thrombosis, urgent revascularization, and
all-cause hospitalization and each individual component. The aim is to enroll approximately 4,600 patients
from around 500 sites in 33 countries.
Summary:AUGUSTUSwill provide insight into the optimal oral antithrombotic therapy strategy for patients with
AF and concomitant coronary artery disease. The unique 2 × 2 factorial design will delineate the bleeding effects
of various anticoagulant and antiplatelet therapies and generate evidence to guide the selection of the optimal
antithrombotic regimen for this challenging group of patients. It is the largest and only prospective randomized
trial to investigate in a blinded fashion the risk and beneﬁts of aspirin on top of a non–vitamin K antagonist oral
anticoagulant and P2Y12 receptor inhibition.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Atrial ﬁbrillation (AF) is themost common cardiac arrhythmia, with
increasing prevalence among the elderly.1 Approximately 20%-30% of
patients with AF also have concomitant coronary artery diseasearticle.
uke Clinical Research Institute,
s).
. This is an open access article under(CAD),2,3 and 5%-10% of patients who undergo percutaneous coronary
intervention (PCI) have AF.4-7 A clinical conundrum arises when pa-
tients with AF on oral anticoagulation develop an acute coronary syn-
drome (ACS) and/or require PCI. Vitamin K antagonists (VKAs) have
not been shown to prevent stent thrombosis and are not indicated for
secondary prevention following an ACS, whereas dual antiplatelet ther-
apy (DAPT) does not provide a large treatment effect in preventing AF-
related strokes.8,9 The addition of dual antiplatelet agents to VKAthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
18 R.D. Lopes et al. / American Heart Journal 200 (2018) 17–23(“triple therapy”) signiﬁcantly increases the risk of bleeding.10,11 Thus,
there is a signiﬁcant unmet need for an oral antithrombotic strategy
with an acceptable beneﬁt/risk proﬁle for the treatment of patients
with AF and concomitant acute CAD.
A triple-therapy strategy in patients on DAPT requiring oral
anticoagulation has been called into question with the publication of the
What is the Optimal antiplatElet and anticoagulant therapy in patients
with oral anticoagulation and coronary StentTing (WOEST) trial, the
ﬁrst trial in which patients undergoing PCI on oral anticoagulation with
a VKA were randomized to either clopidogrel plus aspirin or clopidogrel
without aspirin.12 The results showed that the use of clopidogrel without
aspirin was associated with signiﬁcantly fewer bleeding events without
an apparent increase in ischemic events. WOEST was a pilot study with
573 participants from 2 countries and included indications for oral
anticoagulation other thanAF, so results did not lead to substantial chang-
es in clinical practice guidelines. Nevertheless,WOEST represents the ﬁrst
challenge to the accepted paradigm that aspirin must be a cornerstone of
therapy in patients with concomitant AF and CAD. Current guideline rec-
ommendations aremostly based on expert consensus, and the choice and
duration of triple therapy depend on patient bleeding risk, stroke risk, and
clinical presentation (ACS or elective PCI).13-15
Whereas WOEST used a VKA-based antithrombotic strategy, 2 sub-
sequent trials have evaluated strategies using the non-VKA oral antico-
agulants (NOACs) rivaroxaban and dabigatran. PIONEER AF-PCI
randomized 2,100 patients with AF undergoing PCI to 1 of 3 antithrom-
botic therapy strategies: (1) rivaroxaban 15 mg daily with a P2Y12 in-
hibitor; (2) rivaroxaban 2.5 mg twice daily with aspirin and a P2Y12
inhibitor and transitioning to rivaroxaban 15 mg daily and aspirin
when the P2Y12 inhibitor was stopped; or (3) VKA, aspirin, and a
P2Y12 inhibitor and transitioning to VKA and aspirin when the P2Y12
inhibitor was stopped.16 The trial demonstrated signiﬁcantly less bleed-
ing with each of the reduced-dose rivaroxaban-based antithrombotic
strategies thanwith the VKA strategy, and therewas no apparent differ-
ence in ischemic events, stroke, or stent thrombosis among the 3 treat-
ment strategies.
The RE-DUAL PCI trial randomized 2,725 patients with AF undergo-
ing PCI to 1 of 3 antithrombotic therapy strategies: (1) dabigatran
150 mg twice daily with a P2Y12 inhibitor; (2) dabigatran 110 mg
twice daily with a P2Y12 inhibitor; or (3) VKA, P2Y12 inhibitor, and as-
pirin for 1 month in those receiving a bare metal stent or 3 months in
those receiving a drug-eluting stent.17 The trial demonstrated signiﬁ-
cantly less major or clinically relevant nonmajor (CRNM) bleeding (de-
ﬁned by the International Society on Thrombosis and Haemostasis
[ISTH]) with each of the dabigatran-based antithrombotic strategies
than with the VKA strategy. Although there were no statistically signif-
icant differences in ischemic events, stroke, or stent thrombosis, the
low-dose dabigatran regimen of 110 mg twice daily was associated
with numerically higher rates of stent thrombosis and myocardial in-
farction (MI). Although these trials were important, they were not
powered or designed to assess whether the bleeding reduction was
due to the use of a NOAC or due to the removal of aspirin from the
post-PCI oral antithrombotic strategy. Additionally, in both studies,
lower doses of NOACs were associated with numerically higher rates
of ischemic events.
Rationale for apixaban
In the randomized, double-blind Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)
trial, apixaban 5 mg twice daily was compared with warfarin titrated
to an international normalized ratio (INR) of 2.0 to 3.0 to prevent stroke
and systemic embolism in 18,201 patients with AF.18,19 The rate of the
primary outcome was 1.27% for the apixaban arm versus 1.60% for the
warfarin arm (hazard ratio [HR] 0.79, 95% CI 0.66-0.95; P b .001 for non-
inferiority; P = .01 for superiority). Although the ARISTOTLE study
clearly demonstrated that apixaban 5 mg twice daily was associatedwith lower rates of bleeding and better efﬁcacy than warfarin with an
INR target of 2.0 to 3.0 in the overall AF study population, therewas lim-
ited experiencewith patients whowere also on DAPT. Patients were ex-
cluded from entry into ARISTOTLE if they were on DAPT at the time of
randomization, but if a need for DAPT arose during the trial, this was
allowed at the discretion of the investigator. Use of a single antiplatelet
therapy, predominantly aspirin, was allowed both at initiation and dur-
ing the trial. Aspirin use at baseline was associated with higher major
and CRNM bleeding rates for both apixaban and warfarin without any
signiﬁcant association with ischemic events.20
In the Apixaban for Prevention of Acute Ischemic Events 2 (APPRAISE-
2) study, apixaban was compared with placebo in a patient population
with ACS without an indication for oral anticoagulation predominantly
receiving aspirin or aspirin plus clopidogrel.21 This trial was stopped
early because of an increase in major bleeding without a substantial con-
comitant reduction in ischemic events. In addition, the APPRAISE-2 trial
included very few participants who had documented AF with their
index ACS event, and the study speciﬁcally excluded those patients al-
ready on or with a formal indication for chronic oral anticoagulation.
The optimal treatment of patients with AF who require oral
anticoagulation and develop ACS and/or undergo PCI remains uncertain.
In such circumstanceswhere oral anticoagulation therapy is required to
prevent stroke and systemic embolism and concomitant antiplatelet
therapy is required to minimize the risk of recurrent ischemic events
or stent thrombosis, major bleeding remains a serious concern. The
use of NOACs appears to offer a number of advantages compared with
VKA therapy, including the potential for less bleeding; however, addi-
tional randomized trial data are needed, especially regarding the dis-
continuation of aspirin from the treatment strategy of these patients.
Methods
The Open-Label, 2 × 2 Factorial, Randomized, Controlled Clinical
Trial to Evaluate the Safety of Apixaban vs. Vitamin KAntagonist andAs-
pirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute
Coronary Syndrome and/or Percutaneous Coronary Intervention (AU-
GUSTUS [NCT02415400]) is a large, prospective, multicenter, random-
ized trial with 2 main objectives: (1) to determine whether apixaban
is noninferior to VKA (INR target range 2.0-3.0) for the combined end
point of ISTHmajor and CRNM bleeding in patients with AF who devel-
op ACS and/or undergo PCI with planned concomitant P2Y12 inhibitor
therapy for at least 6 months and (2) to determine whether anticoagu-
lant plus single antiplatelet therapy with a P2Y12 inhibitor for at least
6 months is superior to anticoagulant plus DAPT with a P2Y12 inhibitor
for at least 6 months and aspirin on the combined outcome of ISTH
major and CRNM bleeding in the same population.
The trial plans to enroll around 4,600 patients at approximately 500
sites in 33 countries. The ﬁrst patient was randomized on September 1,
2015, and recruitment is planned to end in April 2018.
This trial is being conducted in compliance with the study protocol,
the Declaration of Helsinki, and Good Clinical Practice, as deﬁned by
the International Conference on Harmonization. Prior to patient partic-
ipation, written informed consent will be obtained from each patient,
and approval will be obtained from appropriate ethics committees at
participating sites.
Study population
Study entry criteria are summarized in Table I. Brieﬂy, patients with
AF and a recent ACS and/or those undergoing PCI with planned treat-
ment with P2Y12 inhibitor for at least 6 months and oral
anticoagulation will be evaluated for eligibility during their ACS and/
or PCI hospitalization. Patients with other conditions that require
anticoagulation (such as prosthetic valves or moderate or severe mitral
stenosis), severe renal insufﬁciency, and history of intracranial hemor-
rhage will be excluded.
Table I
Key inclusion and exclusion criteria
Inclusion criteria 1. Must be ≥18 y of age (or age of majority) with either active or a history of AF or ﬂutter with planned or existing use of an oral anticoagulant
for prophylaxis of thromboembolism
2. Must have had an ACS (STEMI, NSTEMI, or unstable angina) AND/OR a PCI within the prior 14 d
3. Planned use of an approved P2Y12 inhibitor for at least 6 m
Exclusion criteria 1. Conditions other than AF that require chronic anticoagulation (eg, prosthetic mechanical heart valve, DVT, or PE)
2. Severe renal insufﬁciency (serum creatinine N2.5 [221 μmol/L] or a calculated CrCl b30 mL/min
3. Patients with any history of intracranial hemorrhage
4. Any contraindications to VKA, apixaban, intended P2Y12 inhibitors, or aspirin
5. Recent or planned CABG surgery for the index ACS event
6. Patients with known ongoing bleeding
7. Patients with known coagulopathies
STEMI, ST-segment elevationmyocardial infarction;NSTEMI, non–ST-segment elevationmyocardial infarction;DVT, deep vein thrombosis; PE, pulmonary embolism; CrCl, creatinine clear-
ance; CABG, coronary artery bypass graft.
Figure 1. AUGUSTUS trial design.
19R.D. Lopes et al. / American Heart Journal 200 (2018) 17–23Randomization and treatment
The trial schema is shown in Figure 1. Randomization will be per-
formed up to 14 days after the ACS and/or PCI and should take place
as early as possible after cessation of parenteral anticoagulant and
when the patient is clinically stable. The 14-day window was provided
to take into accountworldwide variations in care of this patient popula-
tion, although explicit guidance is provided to enroll and randomize pa-
tients as quickly as possible after the index event once parenteral
anticoagulants have been stopped. Patients with or without prior oral
anticoagulant treatment can be included. Patients who are on a VKA
prior to randomization will have VKA discontinued and will not be
dosed with apixaban until the INR is less than 2.0.
At enrollment, eligible patientswill be randomized via an interactive
voice response system using a 2 × 2 factorial design to either apixaban
or VKA and to either aspirin or aspirin placebo. Randomization will be
stratiﬁed by indication at enrollment (ACS vs PCI). Apixaban or VKA
will be given in an open-label manner, whereas aspirin (or matching
placebo) will be double-blinded. Participants randomized to apixaban
will be dosed at 5 mg twice daily unless they meet ≥2 of the following
criteria for the reduced dose of 2.5 mg twice daily: age ≥ 80 years,
weight ≤ 60 kg, or serum creatinine ≥1.5 mg/dL (133 μmol/L). Partici-
pants randomized to VKA should be titrated up for an INR target goal
of 2.0 to 3.0. Dosage of VKA to achieve that range should be per localstandards of care and per investigator clinical judgment. Patients who
take aspirin prior to randomization will switch to 81 mg aspirin or
matching placebo. Both the oral anticoagulant (apixaban or VKA) and
the antiplatelet agents (blinded aspirin once daily or blinded placebo
once daily) must be started within 24 hours of randomization. During
the 6-month treatment period with VKA or apixaban, other oral or par-
enteral anticoagulants (such as dabigatran, rivaroxaban, edoxaban,
fondaparinux, unfractionated heparin, or low–molecular weight hepa-
rins) may not be given concurrently. The 6-month timewindow for fol-
low-up, with an additional month for safety monitoring, was chosen
because this is the primary period during which the risk of recurrent is-
chemic events is highest andmust beweighed against bleeding risk. Ad-
ditionally, with more recent guidance recommending shorter DAPT in
patients receiving the latest-generation drug-eluting stents and the
known risks of prolonged triple antithrombotic therapy, a longer dura-
tion of follow-upwould lead tomore patients discontinuing their P2Y12
inhibitor during the follow-up period.
Study outcomes
Primary outcomes
The primary outcome will be time to ﬁrst occurrence of ISTH major
or CRNM bleeding during the treatment period for the comparison be-
tween apixaban and VKA and for the comparison between aspirin and
Table II
Clinical events deﬁnitions
ISTH A. Major bleeding
Clinically overt bleeding that is associated with:
• Death (fatal bleeding) or
• Occurs in a critical area or organ or
o Intracranial,
o Intraspinal,
o Intraocular,
o Retroperitoneal,
o Intraarticular,
o Intramuscular with compartment syndrome
o Pericardial
• Transfusion of ≥2 U of PRBC or whole blood
• Fall in hemoglobin of ≥2 g/dL
B. Clinically relevant nonmajor bleeding
Any overt bleeding that meets 1 or more of the following criteria:
• Requires hospitalization
• Requires a physician-guided medical or surgical intervention to treat the bleeding or results in unscheduled contact with a physician
(visit or telephone call) or pain or impairment of daily activities
• Results in a physician-guided change in antithrombotic therapy
C. Minimal bleeding
All other overt bleeding events that do not meet the criteria for a major bleeding event or clinically relevant nonmajor bleeding event.
Stroke Stroke is deﬁned as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of
hemorrhage or infarction that is not due to an identiﬁable nonvascular cause (ie, brain tumor, trauma, brain procedures, metabolic condition) that is:
1. Not reversible within 24 h or results in death (in b24 h) or
2. Resolves in b24 h and is accompanied by clear evidence of a new stroke on cerebral imagingAll strokes will be classiﬁed as ischemic,
hemorrhagic, or undetermined.
MI Acute MI refers to evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia.
1. Detection of a rise and/or fall of cardiac biomarker values (preferably cTn) with at least 1 value above the URL and with at least 1 of the following:
• Symptoms of ischemia
• New or presumed new signiﬁcant ST-segment T-wave changes or new LBBB
• Development of pathological Q waves in the ECG
• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
• Identiﬁcation of an intracoronary thrombus by angiography or autopsy
2. Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or new LBBB, but death occurred
before cardiac biomarkers were obtained or before cardiac biomarker values would be increased.
3. PPCI-related MI is deﬁned by elevation of cTn values (N5× URL) or a rise of cTn values N20% if the baseline values are elevated and are stable
or falling. In addition, at least 1 of the following is required:
• Symptoms suggestive of myocardial ischemia
• New ischemic ECG changes
• Angiographic ﬁndings consistent with a procedural complication
• Imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality
4. Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of evidence of myocardial ischemia
and with a rise and/or fall of cardiac biomarker values with at least 1 value above the 99th percentile URL
5. CABG-related MI is deﬁned by elevation of troponin values (N10× URL) in patients with normal baseline cTn values (≤URL). In addition, at
least 1 of the following is required:
• New pathological Q waves or new LBBB
• Angiographically documented new graft or new native coronary artery occlusion
• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Cardiac troponin is the preferred biomarker for diagnosis of MI. In the absence of troponin, CK-MB will be used.
Stent thrombosis Stent thrombosis will be classiﬁed as acute, subacute, late, and very late stent thrombosis. Stent thrombosis categories include:
• Deﬁnite stent thrombosis
• Probable stent thrombosis
• Possible stent thrombosis
Death All deaths will be categorized as cardiovascular, noncardiovascular, or undetermined
In addition, all deaths will further be subclassiﬁed based on speciﬁc cardiovascular and noncardiovascular categories.
PRBC, packed red blood cells; cTn, cardiac troponin; URL, upper reference limit; LBBB, left bundle-branch block; ECG, electrocardiograph; CK, creatine kinase.
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hemoglobin drop of at least 2 g/dL or transfusion of ≥2 U of packed red
cells, or bleeding occurring at a critical site or resulting in death. CRNM
bleeding is deﬁned as any overt bleeding that does not meet criteria
for major bleeding and meets 1 or more of the following criteria: re-
quires hospitalization; requires a physician-guided medical or surgical
intervention to treat the bleeding, or results in unscheduled contact
with a physician (visit or telephone call), or results in pain or impair-
ment of daily activities; or results in a physician-guided change in anti-
thrombotic therapy. Outcomes will be adjudicated according to
standard deﬁnitions by an independent committee blinded to treat-
ment assignment (Table II).
Secondary outcomes
Secondary outcomes for the comparison of apixaban with VKA in-
clude superiority for the outcomes of ISTH major or CRNM bleeding;
the composite end point of all-cause death and all-cause hospitaliza-
tion; the composite end point of all-cause death, stroke, MI, stent
thrombosis, and urgent revascularization; and ﬁrst hospitalization for
any cause. A key prespeciﬁed secondary outcome is the composite of
all-cause death and all-cause hospitalization. Secondary outcomes for
the comparison of aspirin versus placebo include the composite end
point of all-cause death, stroke, MI, stent thrombosis, and urgent revas-
cularization and ﬁrst hospitalization for any cause. A prespeciﬁed sec-
ondary outcome for the comparison of aspirin with placebo is the
composite of all-cause death and all-cause hospitalization.
Exploratory outcomes
Exploratory outcomes for the comparison of apixabanwith VKA and
for aspirinwith placebo include ISTHmajor bleeding, net clinical beneﬁt
(composite of all-cause death/ischemic events andmajor bleeding), all-
cause death, cardiovascular death, MI, stroke, stent thrombosis, urgent
revascularization, and all-cause hospitalization.
Sample size calculation and statistical analysis
This study is designed to evaluate 2 safety hypotheses in patients
with AF with recent ACS and/or PCI: (1) apixaban is noninferior to
VKA for the combined outcome of ISTH major and/or CRNM bleeding,
and (2) single antiplatelet therapy with a P2Y12 inhibitor is superior
to DAPT with a P2Y12 inhibitor and aspirin for the combined outcome
of ISTH major and/or CRNM bleeding.
A total of 357 primary end point events in 4,600 participants will
provide 77% power for the test of noninferiority using a stratiﬁed log-
rank test of apixaban compared with VKA, assuming a noninferiority
margin of 1.2, withmajor or CRNMbleeding event rates in the apixaban
and VKA groups of 8.1% and 9% per half year, respectively; a 1-sided sig-
niﬁcance level of .025; and 6-month follow-up and 1% per year of loss to
follow-up. The noninferiority margin was selected because an absolute
risk difference of 1.8% (20% of VKA event rate of 9%) in bleeding is con-
sidered to be a clinically meaningful difference. This sample size will
also provide at least 77.5% power for superiority testing of apixaban
comparedwith VKA, assuming a risk reduction of 25% and a 2-sided sig-
niﬁcance level of .05.
A blinded assessment of the primary outcome event ratewill be per-
formed after 50% of participants have completed the study. The analysis
will focus on the aggregate event rate, and the sample size may be in-
creased if the aggregate event rate is lower than anticipated. The sample
sizemay be adjusted (depending on availability of resources) to provide
sufﬁcient power for both noninferiority and superiority testing of the
primary outcome between apixaban and VKA.
The primary safety data set will consist of all patients who receive at
least 1 dose of study drug. A secondary data set, the evaluable patient
data set, will exclude data from thosewith protocol deviations expected
to affect the primary safety outcome. For the primary safety outcome,
analyses will be performed using the evaluable patient data set as wellas the primary safety data set. For other safety outcomes, analyses will
be performed using the primary safety data set. For the efﬁcacy out-
comes, analyses will be performed using data from all randomized pa-
tients regardless of the treatment actually received.
Comparisons between apixaban and VKA
Ahierarchical testing strategywill be used to compare the effects be-
tween apixaban and VKA treatment groups. Noninferiority for the pri-
mary safety outcome of ISTH major or CRNM bleeding will be tested
ﬁrst at a 1-sided ɑ = .025. If noninferiority for the primary safety out-
come (using a noninferiority margin of 1.2) is not demonstrated, then
stop.
If noninferiority for the primary safety outcome is demonstrated,
then superiority for the primary safety outcome will be tested at a 1-
sided ɑ = .025; and in parallel, the superiority for the composite out-
come of all-cause death and all-cause hospitalization will be tested at
a 1-sided ɑ = .025 without type I error rate adjustment, as the 2 end
points serve different purposes. The bleeding outcome will be used to
evaluate the safety of apixaban, and the efﬁcacy outcome will be used
to demonstrate the effectiveness of apixaban. If the superiority for the
composite outcome of all-cause death and all-cause hospitalization is
not demonstrated, then stop.
If the superiority for the composite outcome of all-cause death and
all-cause re-hospitalization is demonstrated, then superiority for the
composite outcome of death and ischemic events will be tested at a 1-
sided ɑ= .025. If the superiority is not demonstrated, then stop.
If the superiority is demonstrated, then superiority for time to ﬁrst
hospitalization for all-cause hospitalization will be tested at a 1-sidedɑ= .025.
The analysis of theprimary safety outcomewill be performedusing a
Cox proportional-hazards model including treatment group as a covar-
iate and stratiﬁed by indication at enrollment (nonemergent PCI or ACS)
and antiplatelet use (aspirin placebo or aspirin). A point estimate and 2-
sided 95% CI for HRs and a P value for the test of equality of rates (HR=
1) will be calculated. Noninferiority will be demonstrated if the upper
bound of the 2-sided 95% CI for the HR is less than 1.2.
Event rates for the exploratory outcomes will be summarized by
apixaban and VKA treatment group. Point estimates and 2-sided 95%
CIs for HRs will be constructed for the outcome using the methods de-
scribed for the primary outcome, and nominal P values will also be
provided.
Comparisons between aspirin and aspirin placebo
Although no formal statistical testingwill be performed for the com-
parisons between aspirin- and placebo-treated groups, analyses for the
primary, secondary, and other outcomes will be reported (similar to
that done for the apixaban and VKA comparison) but with nominal P
values. The statistical framework of the trial, including the sample size
calculation, was designed for the apixaban and VKA comparison.
Clinical events classiﬁcation committee
Clinical events classiﬁcation of all end points will be led by the Duke
Clinical Research Institute (DCRI) (Durham, NC). All suspected death,
MI, unstable angina, stroke, transient ischemic attack, bleeding events,
and stent thrombosis will be adjudicated in a blinded manner. Causes
of hospitalization will be classiﬁed as cardiovascular, bleeding, or
other. Each potential event will be adjudicated by 2 physicians, and dis-
agreements will be reviewed by a physician committee. The adjudicat-
ing members of the DCRI Clinical Events Classiﬁcation group will
remain blinded to all treatment assignments (including the open-label
apixaban vs VKA arm) throughout the adjudication process and the du-
ration of the trial. Event deﬁnitions are provided in Table II.
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The AUGUSTUS executive committee is led by theDCRI and oversees
the design, execution, analysis, and reporting of the study. This commit-
tee will convene regularly to address policy issues and monitor study
progress, execution, and management. The steering committee com-
prises the national leaders from each participating country and will
meet periodically to discuss the progress of the study. All primary and
secondary analyses of this study will be performed and led by the DCRI.
An independent datamonitoring committee, composed of 2 cardiol-
ogists and 1 statistician, will review serious adverse events, adverse
drug effects, and primary outcome data on a 6-month basis and report
to the executive committee.
There will not be a formal interim analysis during the trial, thus no
intention to “spend” α prior to the ﬁnal analysis and no intention to
stop the trial early for futility or for beneﬁt.
The datamonitoring committeemay recommend termination of the
study for a safety concern that is assessed to outweigh potential
beneﬁts.
Taking into consideration the totality of both bleeding and ischemic
event data, the data monitoring committee may recommend stopping
enrollment and study drug in an arm (or cell) if there is reasonable ev-
idence that a standard-of-care arm or cell (VKA or aspirin) is superior to
a non–standard-of-care arm or cell (apixaban or aspirin placebo) or if
there is proof beyond a reasonable doubt that a non–standard-of-care
arm or cell (apixaban or aspirin placebo) is superior to a standard-of-
care arm or cell (VKA or aspirin). Although no constraining quantitative
guidelines are outlined in the datamonitoring committee charter, there
are broad outlines for recommending the discontinuation of any cell or
randomization arm of the study for either safety or futility.
Depending on the observed results, the data monitoring committee
could recommend continuing the trial as designed or stopping the en-
tire trial, or 1 entire arm (all apixaban, all VKA, all aspirin, or all aspirin
placebo), or 1 single cell (apixaban/aspirin, VKA/aspirin, apixaban/aspi-
rin placebo, or VKA/placebo). If an arm or cell is stopped, additional pa-
tient participants may be randomized into the remaining arms or cells
at the discretion of the executive committee and sponsor.
AUGUSTUS is sponsored by Bristol-Myers Squibb and Pﬁzer.
Discussion
Apixaban was superior to warfarin for the prevention of stroke or
systemic embolism in patients with AF and was associated with lower
rates of bleeding.19 However, little data are available to inform its use
in patients with AF who require concomitant DAPT. Pivotal NOAC trials
in AF excluded patients needing DAPT, whereas DAPT trials following
acute MI and/or PCI excluded patients on oral anticoagulation.19,21-27
AUGUSTUS will help answer important questions about patients with
AF and CAD and has some unique features. First, it is the largest study
in the ﬁeld, including the whole spectrum of patients with CAD (ACS
with or without PCI, and elective PCI). Second, the apixaban dose
(5mg twice daily) used in AUGUSTUS has proven efﬁcacy in stroke pre-
vention in AF. Third, the unique 2 × 2 factorial design will provide in-
sight into whether aspirin may (or may not) be dropped in patients
with AF and CAD receiving oral anticoagulation plus a P2Y12 inhibitor.
Fourth, unlike PIONEER AF-PCI and RE-DUAL PCI, AUGUSTUS does not
exclude patientswith a history of prior stroke, transient ischemic attack,
prior gastrointestinal bleeding, or anemia. Finally, the 6-month follow-
up will delineate bleeding and ischemic events in the highest-risk
time period following the index event. Because the most recent guide-
lines provide a class I indication for DAPT in stable ischemic patients
treated with current drug-eluting stents for 6 months only, patients
will not be subjected to the prolonged DAPT that was used for those re-
ceiving prior-generation drug-eluting stents.14 Moreover, patients may
be enrolledwithin 14 days of the index event (ACS and/or PCI), whereas
in other trials, this time frame was shorter (3-5 days). This will allowmore time before randomization for patients to be treated at the discre-
tion of their physician with any antithrombotic strategy until they are
stable.
In AUGUSTUS, the patient populationwill include both patients with
new-onset AF as well as those already on a stable anticoagulant regi-
men. Permissible baseline anticoagulants at study entry include any
VKA as well as any NOAC, including factor Xa inhibitors or thrombin in-
hibitors. Patients already on oral anticoagulants before randomization
will have the original anticoagulants stopped in accordance with their
labeling prior to randomization and will be transitioned to either VKA
or apixaban.
The 5-mg twice-daily dose of apixaban was chosen because of prov-
en efﬁcacy for stroke reduction comparedwithwarfarin in patientswith
AF. This dose was associated with increased bleeding compared with
placebo in the APPRAISE-2 trial. In AUGUSTUS, however, we are com-
paring apixaban with warfarin. In ARISTOTLE, this same dose of
apixaban was associated with a 31% reduction in major bleeding com-
pared with warfarin. Thus, we believe that apixaban 5 mg twice daily
is the most appropriate dose to be tested in AUGUSTUS to assess efﬁca-
cy, safety, and clinical outcomes in this trial population.
The PIONEER AF-PCI trial provided initial evidence regarding the op-
timal antithrombotic strategy for patients with AF and concomitant cor-
onary disease.16 Although a clear signal of fewer bleeding events was
observed with both regimens including rivaroxaban, the efﬁcacy out-
come (death from cardiovascular causes, MI, and stroke) occurred at
similar rates among treatment arms. This bleeding reduction was ob-
served using doses of rivaroxaban that have not demonstrated proven
efﬁcacy in stroke reduction among patients with AF. Furthermore, the
point estimates for ischemic events were concerning for increased risk
of events, although this study was not powered for efﬁcacy and effects
on ischemic events were imprecise because of wide CIs.
The ﬁndings of the RE-DUAL PCI trial17 generally mirrored those
from PIONEER AF-PCI in that the study demonstrated a reduction in
bleeding in the NOAC arms compared with the traditional VKA-based
triple-therapy arm. It also conﬁrmed the baseline bleeding risk among
patients treated with triple therapy. However, RE-DUAL PCI was unable
to provide insight into whether the reduction in bleeding in the
dabigatran-based armswas due to treatment with dabigatran or the re-
moval of aspirin. Additionally, the trial tested a dose of dabigatran
(110 mg twice daily) that is unavailable in the United States, although
treatment at this dose demonstrated a trend toward an increased risk
ofMI (HR 1.51, 95% CI 0.94–2.41; P= .09) and deﬁnite stent thrombosis
(HR 1.89, 95% CI 0.79–4.40; P = .15) when compared with the corre-
sponding triple-therapy group.
Two other trials of antithrombotic therapy strategies amongpatients
with AF requiring DAPT are ongoing. The Edoxaban Treatment Versus
Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing
Percutaneous Coronary Intervention (ENTRUST-AF PCI) trial28 will ran-
domize 1,500 patients with a history of AF to an edoxaban-based strat-
egy or VKA on top of aspirin and a P2Y12 inhibitor. The study will enroll
patients outside the United States, and results are expected in 2019.
SAFE A29 will randomize 600 patients with AF undergoing PCI with a
drug-eluting stent to 1 month or 6 months of P2Y12 inhibitor therapy
on background apixaban and aspirin, providing guidance on the optimal
duration of an apixaban-based triple-therapy regimen. Theprimary out-
come for both trials will be ISTH major or CRNM bleeding at 1 year.
The ﬁeld of combination antiplatelet and anticoagulant therapy in
high-risk patients is evolving rapidly, and PIONEER AF-PCI and RE-
DUAL PCI provided important randomized data where prior experience
was limited. Nevertheless, AUGUSTUS will extend the ﬁndings of those
trials in important ways and will be the ﬁrst large randomized study to
test the WOEST strategy and distinguish the bleeding contributions of
apixaban and the removal of aspirin. The trial will provide unique infor-
mation that will inform physicians and guidelines on the optimal anti-
thrombotic strategy in these high-risk patients across the spectrum of
CAD.
23R.D. Lopes et al. / American Heart Journal 200 (2018) 17–23Conclusion
AUGUSTUS is the largest trial to date in patients with AF and coro-
nary disease, including those with ACS and/or undergoing PCI, compar-
ing apixaban with VKAs as well as aspirin with placebo in patients
receiving a P2Y12 inhibitor for at least 6 months. The unique features
of this study, including the 2 × 2 factorial design, blinded aspirin/place-
bo comparison, and the inclusion of the entire spectrumof patientswith
coronary disease, will add to the body of evidence to guide the selection
of the optimal antithrombotic regimen for this challenging group of
patients.
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